
|Articles|March 8, 2010
- September 2009
- Volume 3
- Issue 9
Abraxis BioScience Hopes to 'Nab' a Bigger Share of the Taxanes Market
Author(s)Onclive Team
Key Takeaways
- Personalized treatment strategies have advanced the management of lung cancer brain metastases, integrating targeted therapies and immunotherapies for improved outcomes.
- Stereotactic radiosurgery and whole-brain radiation therapy are evolving with new systemic therapies, maintaining their importance in treatment plans.
Advertisement
Articles in this issue
almost 16 years ago
Studies from Around the Globealmost 16 years ago
By the Numbers: If the US Health Care System Had Only 100 Physiciansalmost 16 years ago
In the News Briefsalmost 16 years ago
IASLC's 13th World Conference on Lung CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
5



































